Soliris 300 MG/30 ML vial 30ML
Ended Awarded Last action
- Contract number
- SPE2DR26FMEE3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $41,008
Award facts
- Contract value 100% obligated
- $41,008.16 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $41,008.16 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Soliris 300 mg/30 mL vials. The delivery order was issued on January 7, 2026, with an ultimate completion date of January 29, 2026, and carries no set-aside designation. This award falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy that authorizes firm fixed-price delivery orders for comprehensive pharmaceutical products to support Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical pharmaceutical supplier within the federal supply chain, leveraging its small business status to compete effectively while maintaining consistent performance across multiple therapeutic categories. The company's extensive product portfolio includes branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, with demonstrated delivery order experience ranging from under $100 to over $115,000. As one of multiple regional prime vendor contractors under PPV-G GEN V, which features a 30-month base period with three 30-month option periods extending through December 31, 2036, DMS Pharmaceutical Group has positioned itself to serve critical pharmaceutical needs for military healthcare operations globally with no identified subcontractor relationships in its federal contract awards.
Quick answers
Who was awarded contract SPE2DR26FMEE3?
SPE2DR26FMEE3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 7, 2026.
How much is contract SPE2DR26FMEE3 worth?
The government has obligated $41,008 on SPE2DR26FMEE3.
Is contract SPE2DR26FMEE3 an order under another contract?
Yes. SPE2DR26FMEE3 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEE3 competed?
The extent of competition for SPE2DR26FMEE3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award